A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease (EMPA-KIDNEY)

First published 11/03/2022

Last updated 05/10/2026

EU PAS number:

EUPAS46175

Study

Finalised

Documents

Study protocol

Initial protocol

EMPA-KIDNEY_Protocol_v2p0

English (792.43 KB - PDF) View document

Study results

1245-0137_Synopsis.pdf

English (4.7 MB - PDF) View document

Study report

Other information

Publications

Study publications

Secondary tabs